These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1177 related articles for article (PubMed ID: 19703125)

  • 1. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
    Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
    APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas.
    Amatya VJ; Takeshima Y; Sugiyama K; Kurisu K; Nishisaka T; Fukuhara T; Inai K
    Hum Pathol; 2001 Sep; 32(9):970-5. PubMed ID: 11567227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas.
    Ozen O; Demirhan B; Altinörs N
    Clin Neuropathol; 2005; 24(5):219-24. PubMed ID: 16167545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.
    Engenhart-Cabillic R; Farhoud A; Sure U; Heinze S; Henzel M; Mennel HD; Bertalanffy H
    Strahlenther Onkol; 2006 Nov; 182(11):641-6. PubMed ID: 17072521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SPARC: a potential diagnostic marker of invasive meningiomas.
    Rempel SA; Ge S; Gutiérrez JA
    Clin Cancer Res; 1999 Feb; 5(2):237-41. PubMed ID: 10037170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caveolin-1 in meningiomas: expression and clinico-pathological correlations.
    Barresi V; Cerasoli S; Paioli G; Vitarelli E; Giuffrè G; Guiducci G; Tuccari G; Barresi G
    Acta Neuropathol; 2006 Nov; 112(5):617-26. PubMed ID: 16850311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of SPARC expression and basement membrane intactness at the tumour-brain border of invasive meningiomas.
    Schittenhelm J; Mittelbronn M; Roser F; Tatagiba M; Mawrin C; Bornemann A
    Neuropathol Appl Neurobiol; 2006 Oct; 32(5):525-31. PubMed ID: 16972886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas.
    Torp SH; Lindboe CF; Grønberg BH; Lydersen S; Sundstrøm S
    Clin Neuropathol; 2005; 24(4):170-4. PubMed ID: 16033133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression.
    Abdelzaher E; El-Gendi SM; Yehya A; Gowil AG
    Br J Neurosurg; 2011 Dec; 25(6):707-13. PubMed ID: 20979437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up.
    Lanzafame S; Torrisi A; Barbagallo G; Emmanuele C; Alberio N; Albanese V
    Pathol Res Pract; 2000; 196(7):483-8. PubMed ID: 10926326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [P53 protein expression and proliferative potential in non-recurrent and recurrent meningiomas].
    Miyagami M; Kanou T; Nakamura S
    No To Shinkei; 1996 Aug; 48(8):719-25. PubMed ID: 8797205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proliferation and progesterone receptor status in benign meningiomas are not age dependent.
    Roser F; Nakamura M; Ritz R; Bellinzona M; Dietz K; Samii M; Tatagiba MS
    Cancer; 2005 Aug; 104(3):598-601. PubMed ID: 15952201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does protein expression predict recurrence of benign World Health Organization grade I meningioma?
    Kärjä V; Sandell PJ; Kauppinen T; Alafuzoff I
    Hum Pathol; 2010 Feb; 41(2):199-207. PubMed ID: 19801161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between laminin γ1 expression and meningioma grade, recurrence, and progression-free survival.
    Ke HL; Ke RH; Li B; Wang XH; Wang YN; Wang XQ
    Acta Neurochir (Wien); 2013 Jan; 155(1):165-71. PubMed ID: 23053286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of apoptotic and proliferation markers in meningiomas.
    Konstantinidou AE; Pavlopoulos PM; Patsouris E; Kaklamanis L; Davaris P
    J Pathol; 1998 Nov; 186(3):325-30. PubMed ID: 10211124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Proliferative markers of meningiomas: immunohistochemical analysis and prognostic value].
    Korshunov AG; Shishkina LV; Golanov AV
    Arkh Patol; 2002; 64(1):29-33. PubMed ID: 11889696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases.
    Roser F; Samii M; Ostertag H; Bellinzona M
    Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of extracellular matrix-degrading proteins in classic, atypical, and anaplastic meningiomas.
    von Randow AJ; Schindler S; Tews DS
    Pathol Res Pract; 2006; 202(5):365-72. PubMed ID: 16563650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD44 expression in human meningiomas: an immunohistochemical analysis.
    Lewy-Trenda I; Omulecka A; Janczukowicz J; Papierz W
    Pol J Pathol; 2004; 55(1):33-7. PubMed ID: 15195704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of p63 immunoreactivity with tumor grade in meningiomas.
    Rushing EJ; Olsen C; Man YG
    Int J Surg Pathol; 2008 Jan; 16(1):38-42. PubMed ID: 18203782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.